Online inquiry

IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9416MR)

This product GTTS-WQ9416MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PTPRC gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001267798.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5788
UniProt ID P08575
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9416MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15213MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ5400MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ3081MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ625MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10289MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ6573MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ9898MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ9145MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN-289
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW